References
- Pleyer U, Pohlmann D, Kardeş E, et al. Emerging drugs for the treatment of noninfectious uveitis. Expert Opin Emerg Drugs 2019;24:173–190.
- Cordero-Coma M, Salazar-Mendez R, Garzo-Garcia I, et al. Drug-induced uveitis. Expert Opin Drug Saf 2015;14:111–126.
- Anquetil C, Salem JE, Lebrun-Vignes B, et al. Evolving spectrum of drug-induced uveitis at the era of immune checkpoint inhibitors results from the WHO's pharmacovigilance database. J Autoimmun 2020;111:102454.
- Granier C, De Guillebon E, Blanc C, et al. Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer. ESMO Open 2017;2:e000213.
- Barbee MS, Ogunniyi A, Horvat TZ, et al. Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology. Ann Pharmacother 2015;49:907–937.
- Das S, Johnson DB. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer 2019;7:306.
- Sullivan RJ, Weber JS. Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies. Nat Rev Drug Discov 2022;21:495–508.
- Dalvin LA, Shields CL, Orloff M, et al. CHECKPOINT INHIBITOR IMMUNE THERAPY: Systemic indications and ophthalmic side effects. Retina 2018;38:1063–1078.
- Bristol-Myers Squibb Company, Princeton, NJ. YERVOY® (ipilimumab) [package insert]. 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125377s124lbl.pdf
- Bristol-Myers Squibb Company, Princeton, NJ. OPDIVO® (nivolumab) [package insert]. 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125554s108lbl.pdf
- Merck Sharp & Dohme Corp, Whitehouse Station, NJ. KEYTRUDA® (pembrolizumab) [package insert]. 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125514s110lbl.pdf
- Genentech Inc, South San Francisco, CA. TECENTRIQ® (atezolizumab) [package insert]. 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761034s043lbl.pdf
- EMD Serono Inc, Rockland, MA. BAVENCIO® (avelumab) [package insert]. 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761049s005lbl.pdf
- AstraZeneca Pharmaceuticals LP, Wilmington, DE. IMFINZI® (durvalumab) [package insert]. 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761069s032lbl.pdf
- Regeneron Pharmaceuticals Inc, Tarrytown, NY. LIBTAYO® (cemiplimab-rwlc) [package insert]. 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761097s007lbl.pdf
- Numata S, Iwata Y, Okumura R, et al. Bilateral anterior uveitis and unilateral facial palsy due to ipilimumab for metastatic melanoma in an individual with human leukocyte antigen DR4: a case report. J Dermatol 2018;45:113–114.
- Kikuchi R, Kawagoe T, Hotta K. Vogt-Koyanagi-Harada disease-like uveitis following nivolumab administration treated with steroid pulse therapy: a case report. BMC Ophthalmol 2020;20:252–32580711.
- Dolaghan MJ, Oladipo B, Cooke CA, et al. Metastatic melanoma and immunotherapy-related uveitis: an incidence in Northern Ireland. Eye (Lond)) 2019;33:1670–1672.
- Jing Y, Yang J, Johnson DB, et al. Harnessing big data to characterize immune-related adverse events. Nat Rev Clin Oncol 2022;19:269–280.
- Bomze D, Meirson T, Hasan Ali O, et al. Ocular adverse events induced by immune checkpoint inhibitors: a comprehensive pharmacovigilance analysis. Ocul Immunol Inflamm 2022;30:191–197.
- Fang T, Maberley DA, Etminan M. Ocular adverse events with immune checkpoint inhibitors. J Curr Ophthalmol 2019;31:319–322.
- Fukazawa C, Hinomura Y, Kaneko M, et al. Significance of data mining in routine signal detection: Analysis based on the safety signals identified by the FDA. Pharmacoepidemiol Drug Saf 2018;27:1402–1408.
- Harpaz R, DuMouchel W, LePendu P, et al. Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system. Clin Pharmacol Ther 2013;93:539–546.
- MedDRA MSSO. Introductory Guide for Standardised MedDRA Queries (SMQs) Version 23.1 2020. https://admin.new.meddra.org/sites/default/files/guidance/file/SMQ_intguide_23_1_English.pdf
- Poluzzi E, Raschi E, Piccinni C, et al. Data mining techniques in pharmacovigilance: analysis of the publicly accessible FDA Adverse Event Reporting System (AERS). Data Mining Applications in Engineering and Medicine 2012. https://api.intechopen.com/chapter/pdf-preview/38579
- van Puijenbroek EP, Bate A, Leufkens HG, et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf 2002;11:3–10.
- Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 2001;10:483–486.
- Bate A, Lindquist M, Edwards IR, et al. A bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 1998;54:315–321.
- Szarfman A, Machado SG, O'Neill RT. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database. Drug Saf 2002;25:381–392.
- Sakaeda T, Tamon A, Kadoyama K, et al. Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci 2013;10:796–803.
- Kono K, Nakajima S, Mimura K. Current status of immune checkpoint inhibitors for gastric cancer. Gastric Cancer 2020;23:565–578.
- Akinleye A, Rasool Z. Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. J Hematol Oncol 2019;12:92.
- El Dika I, Khalil DN, Abou-Alfa GK. Immune checkpoint inhibitors for hepatocellular carcinoma. Cancer 2019;125:3312–3319.
- Krishna U, Ajanaku D, Denniston AK, et al. Uveitis: a sight-threatening disease which can impact all systems. Postgrad Med J 2017;93:766–773.
- Izem R, Sanchez-Kam M, Ma H, et al. Sources of safety data and statistical strategies for design and analysis: Postmarket surveillance. Ther Innov Regul Sci 2018;52:159–169.
- Inacio P, Cavaco A, Airaksinen M. The value of patient reporting to the pharmacovigilance system: a systematic review. Br J Clin Pharmacol 2017;83:227–246.
- Sun MM, Kelly SP, Mylavarapu Bs AL, et al. Ophthalmic Immune-Related adverse events after anti-CTLA-4 or PD-1 therapy recorded in the American academy of ophthalmology intelligent research in sight registry. Ophthalmology 2021;128:910–919.
- O'Connor JM, Seidl-Rathkopf K, Torres AZ, et al. Disparities in the use of programmed death 1 immune checkpoint inhibitors. Oncologist 2018;23:1388–1390.
- Irelli A, Sirufo MM, D’Ugo C, et al. Sex and gender influences on cancer immunotherapy response. Biomedicines 2020;8:232–32708265.
- DePinho RA. The age of cancer. Nature 2000;408:248–254.
- Braun D, Getahun D, Chiu VY, et al. Population-Based frequency of ophthalmic adverse events in melanoma, other cancers, and after immune checkpoint inhibitor treatment. Am J Ophthalmol 2021;224:282–291.
- Arai T, Harada K, Usui Y, et al. Case of acute anterior uveitis and Vogt-Koyanagi-Harada syndrome-like eruptions induced by nivolumab in a melanoma patient. J Dermatol 2017;44:975–976.
- Rapisuwon S, Izar B, Batenchuk C, et al. Exceptional response and multisystem autoimmune-like toxicities associated with the same T cell clone in a patient with uveal melanoma treated with immune checkpoint inhibitors. J Immunother Cancer 2019;7:61.
- Enomoto H, Kato K, Sugawara A, et al. Case with metastatic cutaneous malignant melanoma that developed Vogt-Koyanagi-Harada-like uveitis following pembrolizumab treatment. Doc Ophthalmol 2021;142:353–360.
- de Vries TJ, Trancikova D, Ruiter DJ, et al. High expression of immunotherapy candidate proteins gp100, MART-1, tyrosinase and TRP-1 in uveal melanoma. Br J Cancer 1998;78:1156–1161.
- Sun MM, Levinson RD, Filipowicz A, et al. Uveitis in patients treated with CTLA-4 and PD-1 checkpoint blockade inhibition. Ocul Immunol Inflamm 2020;28:217–227.
- Moorthy RS, Moorthy MS, Cunningham ET.Jr. Drug-induced uveitis. Curr Opin Ophthalmol 2018;29:588–603.
- Dow ER, Yung M, Tsui E. Immune checkpoint inhibitor-associated uveitis: Review of treatments and outcomes. Ocul Immunol Inflamm 2021;29:203–211.
- Alba-Linero C, Alba E. Ocular side effects of checkpoint inhibitors. Surv Ophthalmol 2021;66:951–959.
- Fortes BH, Liou H, Dalvin LA. Ophthalmic adverse effects of immune checkpoint inhibitors: the Mayo clinic experience. Br J Ophthalmol 2021;105:1263–1271.
- Suwa S, Tomita R, Kataoka K, et al. Development of Vogt-Koyanagi-Harada disease-like uveitis during treatment by anti-programmed death ligand-1 antibody for non-small cell lung cancer: a case report. Ocul Immunol Inflamm 2021;30:1522–1526.